6 research outputs found

    Surgical Results of Endoscopic Dacryocystorhinostomy and Lacrimal Trephination in Distal or Common Canalicular Obstruction

    Get PDF
    ObjectivesTo evaluate the surgical outcomes of endoscopic dacryocystorhinostomy followed by canalicular trephination and silicone stenting in patients with distal or common canalicular obstructions.MethodsThe medical records of 29 patients (31 eyes) from January 2001 to December 2009 who underwent endoscopic dacryocystorhinostomy followed by canalicular trephination and silicone tube insertion for the treatment of distal or common canalicular obstructions were retrospectively reviewed. The level of obstruction was confirmed by intraoperative probing. The outcome of the surgery was categorized as a complete success, partial success, or failure according to the functional and anatomic patency.ResultsThe average age of the patients was 52 years. The duration of silicone intubation ranged from 4 to 11 months with an average of 5.7±1.6 months. The follow-up period after stent removal ranged from 4 to 15 months with an average of 8.2±3.3 months. Complete success was achieved in 25 out of 31 eyes (80.6%), partial success in 4 out of 31 eyes (12.9%), and failure in 2 out of 31 eyes (6.5%).ConclusionEndoscopic dacryocystorhinostomy followed by canalicular trephination and silicone stent intubation may be safe and considered as an initial treatment of patients with distal or common canalicular obstructions

    Low-energy formulas for neutrino masses with tanβ\tan \beta-dependent hierarchy

    Full text link
    Using radiative correction and seesaw mechanism,we derive analytic formulas for neutrino masses in SUSY unified theories exhibiting, for the first time, a new hierarchial relation among them.The new hierarchy is found to be quite significant especially for smaller values of tanβ\tan\beta.Comment: 10 pages,REVTEX, no figures,typographical errors rectifie

    Fast matrix multiplication and its algebraic neighborhood

    No full text

    Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

    No full text
    International audienc
    corecore